Is JBIO or JNJ more undervalued in 2026?

CirclFi compares Jade Biosciences, Inc. (JBIO) and Johnson & Johnson (JNJ) using 13 institutional-grade valuation models. JBIO has a Quality of Company score of 4.1/10 while JNJ scores 9.7/10.

Which is a better buy — JBIO or JNJ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JBIO and JNJ valuations compare?

JBIO at $21.04 and JNJ at $225.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JBIO vs JNJ Valuation Comparison 2026 — Intrinsic Value Analysis

JBIO

Pharmaceutical Preparations

Jade Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$21.04

Last close

Models

7/13

Active

JNJ

Pharmaceutical Preparations

Johnson & Johnson

Quality

9.7

out of 10

Value Trap

SAFE

Price

$225.33

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	JBIO Fair Value	JBIO Upside	JNJ Fair Value	JNJ Upside
Bayesian DCF	Intrinsic	$6.33	-69.9%	$76.89	-65.9%
Earnings Power Value	Intrinsic	—	—	$50.60	-77.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.86	-81.7%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JBIO vs JNJ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JBIO vs JNJ — Which Stock Is More Undervalued?

JNJ scores higher with a 9.7/10 quality rating vs JBIO's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jade Biosciences, Inc. (JBIO) and Johnson & Johnson (JNJ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JBIO currently trades at $21.04 with a QOC of 4.1/10, while JNJ trades at $225.33 with a QOC of 9.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).